Warfarin Dosing by CYP2C9/VKORC1 Genotype

Why Genotype-Guided Warfarin Dosing?

Warfarin has a notoriously narrow therapeutic index. Genetic variation in CYP2C9 (metabolism) and VKORC1 (drug target) accounts for ~35–40% of dose variability — more than any clinical factor alone.

⚠️

The Problem Warfarin is among the top causes of drug-related emergency department visits. Over- or under-dosing leads to major bleeding or thromboembolic events.

CYP2C9 — Metabolism

Encodes the primary enzyme metabolizing S-warfarin (the more potent enantiomer)
Loss-of-function variants (*2, *3, *5, *6, *8, *11) reduce clearance
Poor metabolizers accumulate warfarin, increasing bleeding risk
Prevalence of reduced function varies by ancestry

VKORC1 — Drug Target

Encodes vitamin K epoxide reductase — warfarin's molecular target
-1639G>A (rs9923231) is the key regulatory variant
A/A genotype = high sensitivity, requiring ~50% lower doses
Common in East Asian populations (~90% carry at least one A allele)

📋

CPIC Guideline The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides an A-level recommendation for genotype-guided warfarin dosing, the strongest level of evidence for clinical actionability.

💡

FDA Label The warfarin (Coumadin®) FDA label includes a pharmacogenomic dosing table based on CYP2C9 and VKORC1 genotype — one of the first drugs to include PGx dosing guidance.

CYP2C9 Variant Alleles

Key loss-of-function alleles that reduce S-warfarin metabolism and require dose reduction.

*1 (Wild-type)

Reference allele

Normal enzyme activity. Full S-warfarin metabolism.

All populations — reference

*2 (R144C)

rs1799853

~30% reduced activity. Intermediate metabolizer when heterozygous.

~13% European, ~3% African, ~1% East Asian

*3 (I359L)

rs1057910

~80% reduced activity. Significant dose reduction required.

~7% European, ~1% African, ~4% East Asian

rs28371686

No function. Equivalent to *3 for dosing purposes.

Rare across populations

rs9332131

No function. Frameshift causing non-functional enzyme.

~1% African American

rs7900194

Reduced function. Important for African-descent populations.

~5% African American

*11

rs28371685

Reduced function. Clinically actionable per CPIC.

~1% European

🌍

Equity Note CYP2C9 *5, *6, *8, and *11 are more prevalent in individuals of African ancestry and are often missing from commercial PGx panels. Clinicians should ensure comprehensive testing for diverse populations.

VKORC1 Variant & Sensitivity

The -1639G>A promoter variant (rs9923231) determines warfarin sensitivity by affecting VKORC1 expression levels.

Genotype	VKORC1 Expression	Warfarin Sensitivity	Dose Impact
G/G	High expression	Low Sensitivity	Higher doses needed (~6–7 mg/day)
G/A	Intermediate expression	Intermediate	Standard range (~4–5 mg/day)
A/A	Low expression	High Sensitivity	Reduced doses (~2–3 mg/day)

Population Frequencies

East Asian: ~90% carry A allele (high sensitivity common)
European: ~55–60% carry A allele
African: ~15–20% carry A allele
This explains known inter-ethnic dose differences

Clinical Significance

VKORC1 genotype alone explains ~25% of dose variance
A/A patients reach therapeutic INR faster — monitor closely
G/G patients may need prolonged dose titration
Combined with CYP2C9, accounts for 35–40% of total variability

Genotype-Guided Dosing Recommendations

Estimated therapeutic maintenance doses based on combined CYP2C9 and VKORC1 genotype — adapted from CPIC guidelines and FDA labeling.

📊

Note: These are estimated starting dose ranges. All patients require INR monitoring and individualized titration. Clinical factors (age, weight, interacting drugs, diet) also influence dosing.

CYP2C9 Genotype	VKORC1 G/G	VKORC1 G/A	VKORC1 A/A
1/1 (Normal)	5–7 mg/day	3–5 mg/day	2–3 mg/day
1/2 (Intermediate)	4–6 mg/day	3–4 mg/day	1.5–2.5 mg/day
1/3 (Intermediate)	3–5 mg/day	2–3 mg/day	1–2 mg/day
2/2 (Intermediate)	3–4 mg/day	2–3 mg/day	1–2 mg/day
2/3 (Poor)	2–3 mg/day	1–2 mg/day	0.5–1.5 mg/day
3/3 (Poor)	1–2 mg/day	0.5–1.5 mg/day	0.5–1 mg/day

🩸

Poor Metabolizer + High VKORC1 Sensitivity: Patients with CYP2C9 *3/*3 + VKORC1 A/A represent the highest bleeding risk. Consider alternative anticoagulants (DOACs) where clinically appropriate.

Clinical Decision Workflow

A step-by-step approach to implementing genotype-guided warfarin initiation.

Patient requires anticoagulation with warfarin

↓

Order CYP2C9 + VKORC1 genotyping (pre-treatment if possible)

↓

Receive genotype results

↓

Normal metabolizer
+ Low VKORC1 sensitivity
Standard dose (5–7 mg/day)

Intermediate metabolizer
or Intermediate sensitivity
Reduce dose 25–50%

Poor metabolizer
+ High sensitivity
Reduce dose ≥50%
or consider DOAC

↓

Monitor INR within 3–5 days, then weekly until stable

↓

Therapeutic INR 2.0–3.0 achieved → maintenance dosing

Pre-treatment Genotyping

Ideally, obtain CYP2C9 and VKORC1 results before initiating warfarin. If urgent anticoagulation is needed, start with a conservative dose and adjust upon results.

Use Validated Dosing Algorithm

IWPC (International Warfarin Pharmacogenetics Consortium) calculator incorporates genotype, age, weight, height, and interacting medications for a personalized starting dose.

Assess Drug Interactions

CYP2C9 inhibitors (amiodarone, fluconazole, metronidazole) compound genetic effects. Adjust doses accordingly and document in PGx-aware EHR alerts.

Frequent INR Monitoring

Check INR at day 3–5 post-initiation, then at least weekly for 4–6 weeks. Poor metabolizers may take longer to reach steady state.

Document & Alert

Record genotype results in the patient's permanent medical record. Enable CDS (clinical decision support) alerts for future prescribers.

Key Resources & References

Essential guidelines, tools, and calculators for genotype-guided warfarin dosing.

Guidelines

CPIC Guideline for Warfarin — Johnson JA et al., Clin Pharmacol Ther, 2017
FDA Coumadin Label — Pharmacogenomic dosing table included since 2010
ACC/AHA Anticoagulation Guidelines — Support PGx-guided dosing when available
DPWG (Dutch) — Independent European PGx guideline for warfarin

Dosing Calculators

IWPC Algorithm — warfarindosing.org (genotype + clinical factors)
Gage Algorithm — Alternative regression-based model
PharmGKB — Curated PGx annotations and variant data
CPIC Guidelines App — Mobile reference for all CPIC recommendations

Evidence Summary

EU-PACT Trial: PGx-guided dosing improved time in therapeutic range (TTR) in European patients
COAG Trial: Did not show benefit in mixed-ancestry US cohort — highlighting need for comprehensive variant panels
GIFT Trial: PGx-guided dosing reduced composite endpoint of major bleeding, INR ≥4, venous thromboembolism, and death
Meta-analyses: Consistent benefit when algorithm includes ancestry-specific variants

✅

CMS Coverage: Medicare covers pharmacogenomic testing for warfarin when ordered by a treating physician. Many commercial insurers now cover CYP2C9/VKORC1 testing as well.

Pre-Warfarin PGx Checklist

Click each item to mark as completed. Use this before initiating warfarin therapy.

CYP2C9 genotyping ordered (include *2, *3, *5, *6, *8, *11)
VKORC1 -1639G>A (rs9923231) genotyping ordered
Patient ancestry documented for variant interpretation
Baseline INR obtained
Drug interaction screen completed (CYP2C9 inhibitors/inducers)
Dietary vitamin K intake assessed
Genotype results reviewed and interpreted
Starting dose calculated using IWPC or CPIC table
Dose adjustment applied for drug interactions
INR monitoring schedule set (day 3–5, then weekly)
Genotype results documented in EHR/permanent record
CDS alert configured for future prescribers
Patient educated on signs of bleeding and INR self-monitoring
Alternative anticoagulant (DOAC) discussed if poor metabolizer

Warfarin Dosing byCYP2C9 / VKORC1 Genotype